病患控制镇痛帮浦市场-按类型（电子和无线、机械）、应用（糖尿病、肿瘤学、胃肠病学、血液学）、最终用途（医院、专科诊所、门诊手术中心）-全球预测，2024 -2032年

由于医疗机构（尤其是接受外科手术的患者）对有效疼痛管理解决方案的需求不断增长，预计 2024 年至 2032 年间患者自控镇痛泵市场的复合CAGR将超过 4.8%。这些帮浦允许患者在规定的限度内自行施用止痛药，提供个人化的疼痛缓解并提高患者满意度。此外，癌症和关节炎等慢性疾病的盛行率不断上升，通常需要长期的疼痛管理，推动了该行业的成长。

製造商不断开发具有增强功能的患者控制镇痛泵，例如可编程剂量选项、用于远端监控的无线连接以及易于使用的人体工学设计。这些技术进步提高了泵浦的性能、安全性和使用者体验。此外，智慧帮浦技术与电子病历系统的整合简化了文件记录并增强了药物管理实务。 2021 年 3 月，史密斯医疗公司发布了 CADD(R)-Solis v4 的 ECRI 评估报告，其中包括病患自控镇痛药 (PCA) 和硬膜外输液帮浦的无线通讯功能。

病人自控式镇痛泵产业根据类型、应用、最终用途和地区进行细分。

到 2032 年，血液学领域将显着成长。接受血液学相关手术（例如骨髓活检、造血干细胞移植或血液恶性肿瘤化疗）的患者经常会经历疼痛，需要有效的疼痛管理解决方案。这些帮浦提供个人化和受控的疼痛缓解方法，让患者可以根据需要在规定限度内自行给药。这种程度的自主权使患者能够有效地管理疼痛，从而改善疼痛控制，减少阿片类药物的消耗，并提高患者的整体满意度。

由于成本效益、便利性和微创技术的进步，门诊手术越来越多地转向门诊手术，门诊手术中心预计在 2024 年至 2032 年期间将产生可观的收入。此外，患者自控式镇痛泵的紧凑尺寸和便携性使其非常适合在空间有限且移动性至关重要的 ASC 中使用。

受该地区人口迅速老化和慢性病患病率上升的推动，到 2032 年，亚太地区患者自控镇痛泵产业将实现显着增长。人们越来越多地采用以患者为中心的护理方法，并强调改善患者的治疗结果。中国、日本和印度等国家医疗保健基础设施的进步和医疗保健支出的增加正在刺激区域产业的扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 慢性疼痛的盛行率不断增加
    • 泵浦技术的进步
    • 外科手术数量不断增加
    • 老年人口不断增加
  • 产业陷阱与挑战
    • PCA泵浦成本高
    • 感染和併发症的风险
• 成长潜力分析
• 监管环境
  • 我们
  • 欧洲
• 波特的分析
• PESTEL分析
• 未来市场趋势
• 技术景观
• 定价分析
• 缺口分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2018 - 2032

• 主要趋势
• 电子和无线
• 机械的

第 6 章：市场估计与预测：按应用，2018 - 2032

• 主要趋势
• 肿瘤学
• 糖尿病
• 血液学
• 胃肠病学
• 其他应用

第 7 章：市场估计与预测：按最终用途，2018 - 2032 年

• 主要趋势
• 医院
• 专科诊所
• 门诊手术中心
• 其他最终用户

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Abbott Laboratories
• Ace-medical
• B. Braun Medical Inc.
• Becton, Dickinson and Company
• Changzhou Medical Bioengineering Co., Ltd.
• Fresenius SE & Co. KGaA
• Henan Tuoren Medical Device Co., Ltd.
• ICU Medical, Inc.
• Micrel Medical Devices SA
• SCW MEDICATH LTD.

Patient-controlled analgesic pumps market is anticipated to register a CAGR of over 4.8% between 2024 and 2032, driven by increasing demand for effective pain management solutions in healthcare settings, particularly among patients undergoing surgical procedures. These pumps allow patients to self-administer pain medication within prescribed limits, providing personalized pain relief and enhancing patient satisfaction. Additionally, the rising prevalence of chronic conditions such as cancer and arthritis, which often require long-term pain management, drives the industry growth.

Manufacturers are continuously developing patient-controlled analgesic pumps with enhanced features such as programmable dosing options, wireless connectivity for remote monitoring, and ergonomic designs for ease of use. These technological advancements improve pump performance, safety, and user experience. Moreover, the integration of smart pump technology with electronic medical records systems streamlines documentation and enhances medication management practices. In March 2021, Smiths Medical issued the ECRI evaluation report for the CADD(R)-Solis v4, featuring wireless communication for the Patient-Controlled Analgesic (PCA) and epidural infusion pump.

Patient-controlled analgesic pumps industry is segmented based on type, application, end-use, and region.

Hematology segment will record a notable growth through 2032. The patients undergoing hematology-related procedures, such as bone marrow biopsies, hematopoietic stem cell transplants, or chemotherapy for hematological malignancies, often experience pain requiring effective pain management solutions. These pumps offer a personalized and controlled approach to pain relief, allowing patients to self-administer medication as needed within prescribed limits. This level of autonomy empowers patients to manage their pain effectively, leading to improved pain control, reduced opioid consumption, and enhanced overall patient satisfaction.

Ambulatory surgical centers segment is slated to generate notable revenues during 2024-2032, attributed to the increasing shift towards outpatient surgical procedures due to cost-effectiveness, convenience, and advancements in minimally invasive techniques. Additionally, the compact size and portability of patient-controlled analgesic pumps make them well-suited for use in ASCs, where space may be limited, and mobility is essential.

Asia Pacific patient-controlled analgesic pumps industry will record a notable growth through 2032, backed by the region's rapidly aging population and increasing prevalence of chronic diseases. There is a growing adoption of patient-centered care approaches and emphasis on improving patient outcomes. The advancements in healthcare infrastructure and rising healthcare expenditure in countries like China, Japan, and India are stimulating the regional industry expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & working
• 1.3 Data collection
• 1.4 Forecast calculations
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic pain conditions
    • 3.2.1.2 Advancements in pump technologies
    • 3.2.1.3 Growing number of surgical procedures
    • 3.2.1.4 Rising geriatric population
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of PCA pumps
    • 3.2.2.2 Risk of infection and complications
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis
• 3.7 Future market trends
• 3.8 Technological landscape
• 3.9 Pricing analysis
• 3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Electronic and wireless
• 5.3 Mechanical

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oncology
• 6.3 Diabetes
• 6.4 Hematology
• 6.5 Gastroenterology
• 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Ambulatory surgical centers
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Ace-medical
• 9.3 B. Braun Medical Inc.
• 9.4 Becton, Dickinson and Company
• 9.5 Changzhou Medical Bioengineering Co., Ltd.
• 9.6 Fresenius SE & Co. KGaA
• 9.7 Henan Tuoren Medical Device Co., Ltd.
• 9.8 ICU Medical, Inc.
• 9.9 Micrel Medical Devices SA
• 9.10 SCW MEDICATH LTD.